Brought to you by 
Sinopharm nets HKD3.4bn in FOPO on HKE
26 Aug 2011
Executive Summary
Two years after completing its HKD8.73bn IPO, Sinopharm Group Co. Ltd., China’s largest drug distributor, has netted HKD3.4bn ($436mm) in a secondary placement of 138mm H shares at HKD25 on the Hong Kong Stock Exchange. Proceeds will help fund the many acquisitions the company plans over the next two years to expand its distribution network.
Deal Industry
- Distributors
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sinopharm nets HKD3.4bn in FOPO on HKE
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice